Imfinzi, tremelimumab combo boosts survival in lung cancer
A combination of AstraZeneca’s Imfinzi (durvalumab), tremelimumab and chemotherapy has extended overall survival (OS) when used as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). A final analysis of data from the POSEIDON study shows that the combination demonstrated a statistically significant and clinically meaningful OS benefit versus chemotherapy alone.